From the Back Cover:
Ibogaine is an indole alkaloid derived from the bark of the root of the African shrub Tabernanthe iboga, which has a history of use as a sacramental psychopharmacological agent in West Central Africa. Published scientific evidence for ibogaine's effectiveness as a treatment for drug addiction includes studies showing reduced drug self-administration and withdrawal in animals, and case reports in humans. Ibogaine's mechanism of action appears to differ from those of other existing pharmacotherapeutic approaches to addiction and suggests possible normalizing effects on neural signal transduction that may attenuate or reverse abnormal neuroadaptations in drug tolerance and dependence. The iboga alkaloids appear to offer a new pharmacological approach that may provide a paradigm for understanding the neurobiology of addiction and for developing new medications. However, ibogaine is not currently an approved treatment option in the United States.
The First International Conference on Ibogaine, held at the New York University School of Medicine in November 1999, offered a lively and productive discussion on ibogaine from pharmacological, clinical, and cultural perspectives. The meeting brought together distinguished researchers in basic and clinical neurosciences, anthropology, and sociology, representing academia, the U.S. Food and Drug Administration (FDA), the National Institute on Drug Abuse (NIDA), and the pharmaceutical industry, as well as former "guides" from the informal treatment context. The interdisciplinary meeting agenda emphasized ibogaine's mechanism of action, including interactions with specific neurotransmitter systems, preclinical models of drug self-administration, and discrimination studies, as well as information on noribogaine, ibogaine's principal metabolite, and 18-methoxycoronaridine, a promising new ibogaine congener. Also discussed was the use of ibogaine in European and U.S. subcultures, in African religion and medicine, and how an understanding of the use of ibogaine in these settings could be applied to accessing hidden populations and optimizing the clinical milieu of current conventional treatment.
Key Features
· Interdisciplinary and comprehensive in scope-spans the fields of basic and clinical neurosciences, psychopharmacology, anthropology, and sociology
· The first English-language scientific book devoted to the subject of ibogaine
* Provides up-to-date information regarding ibogaine's mechanism of action, including interactions with specific neurotransmitter systems, preclinical models of drug self-administration, and discrimination studies, as well as information on noribogaine, ibogaine's principal metabolite, and 18-methoxycoronaridine, a promising new ibogaine congener
* Includes a history and sociological analysis of the nonmedical "informal" treatment contexts of Europe and the United States, which have existed for more than three decades despite ibogaine's lack of official approval
* Includes contributions from former "treatment guides," in addition to respected authors from academia, NIDA, and the FDA|Ibogaine is an indole alkaloid derived from the bark of the root of the African shrubTabernanthe iboga, which has a history of use as a sacramental psychopharmacological agent in West Central Africa. Published scientific evidence for ibogaine's effectiveness as a treatment for drug addiction includes studies showing reduced drug self-administration and withdrawal in animals, and case reports in humans. Ibogaine's mechanism of action appears to differ from those of other existing pharmacotherapeutic approaches to addiction and suggests possible normalizing effects on neural signal transduction that may attenuate or reverse abnormal neuroadaptations in drug tolerance and dependence. Theiboga alkaloids appear to offer a new pharmacological approach that may provide a paradigm for understanding the neurobiology of addiction and for developing new medications. However, ibogaine is not currently an approved treatment option in the United States.
The First International Conference on Ibogaine, held at the New York University School of Medicine in November 1999, offered a lively and productive discussion on ibogaine from pharmacological, clinical, and cultural perspectives. The meeting brought together distinguished researchers in basic and clinical neurosciences, anthropology, and sociology, representing academia, the U.S. Food and Drug Administration (FDA), the National Institute on Drug Abuse (NIDA), and the pharmaceutical industry, as well as former "guides" from the informal treatment context. The interdisciplinary meeting agenda emphasized ibogaine's mechanism of action, including interactions with specific neurotransmitter systems, preclinical models of drug self-administration, and discrimination studies, as well as information on noribogaine, ibogaine's principal metabolite, and 18-methoxycoronaridine, a promising new ibogaine congener. Also discussed was the use of ibogaine in European and U.S. subcultures, in African religion and medicine, and how an understanding of the use of ibogaine in these settings could be applied to accessing hidden populations and optimizing the clinical milieu of current conventional treatment.
Key Features
· Interdisciplinary and comprehensive in scope-spans the fields of basic and clinical neurosciences, psychopharmacology, anthropology, and sociology
· The first English-language scientific book devoted to the subject of ibogaine
* Provides up-to-date information regarding ibogaine's mechanism of action, including interactions with specific neurotransmitter systems, preclinical models of drug self-administration, and discrimination studies, as well as information on noribogaine, ibogaine's principal metabolite, and 18-methoxycoronaridine, a promising new ibogaine congener
* Includes a history and sociological analysis of the nonmedical "informal" treatment contexts of Europe and the United States, which have existed for more than three decades despite ibogaine's lack of official approval
* Includes contributions from former "treatment guides," in addition to respected authors from academia, NIDA, and the FDA
About the Author:
Professor Emeritus Geoffrey A. Cordell obtained his Ph.D. in synthetic natural product chemistry at the University of Manchester in 1970. After two years as a NATO postdoctoral fellow at the Department of Chemistry, M.I.T., he joined the College of Pharmacy, University of Illinois at Chicago (UIC). A Professor since 1980, he served as a Department Head for 12 years and as Interim Dean of the College of Pharmacy for almost three years, as well as holding several other senior academic and research administrative positions at the Department, College, and Campus levels. He was the Co-founder of the US - Thai Consortium for Pharmacy Education, which developed and trained faculty for six new schools of pharmacy in Thailand. He retired from the University of Illinois in 2007. Since 1983, he has served as President of Natural Products Inc., a consulting company.
He is the author of about 600 research publications, book chapters, comprehensive reviews and professional publications; is the author of two books, with three more in progress; the editor of 37 books, including 29 volumes in the series “The Alkaloids: Chemistry and Biology ; is Associate Editor-in-Chief of the Chinese Journal of Natural Medicines; and a member of the Editorial Advisory Board of 26 international scientific journals. He is a former President of the American Society of Pharmacognosy, and is also an Honorary Member.
In 1981, he was an Alexander von Humboldt Fellow at the University of Munich with Professor Hildebert Wagner. He is an elected Fellow of the Royal Chemical Society, the Linnean Society of London, the American Society of Pharmacognosy, and the American Association of Pharmaceutical Scientists. In addition to assisting international organizations and corporations in several countries around the world to develop their research and academic programs, he is an Honorary Professor at Sichuan University, Chengdu, China; and at Amity University, Noida, India. He is also a Visiting Professor at universities in Peru, Malaysia, and Brasil, and an International Collaborative Partner of the UTAR Global Research Network in Malaysia in the areas of biodiversity and cancer. In addition, he is a member of the International Advisory Board of several natural product research institutes. His interests include the chemistry and biosynthesis of alkaloids, the sustainability and quality control of medicinal agents, the remote detection of biologically active natural products, and the use of vegetables as chemical reagents.
"About this title" may belong to another edition of this title.